A researcher at the Medical University of South Carolina (MUSC) College of Nursing is conducting a study to better understand supportive care needs and quality of life among individuals with ADVANCED forms of prostate cancer and is seeking just a few more participants to complete this survey. Can you help (if you haven’t already)?
If you live in the USA or its territories and are a patient with ADVANCED (i.e., recurrent, non-localized, or metastatic) prostate cancer, you are potentially eligible to participate.
Individuals with advanced prostate cancer who live in the USA are initially invited to participate in this online survey and you may also volunteer for a follow-up interview once you have completed the survey. In return for your time and effort, some compensation may be available.
It will take you about 15 to 20 minutes to complete the survey, maybe less. The study poses no physical, social, or legal risks. The researchers will take every possible measure to maintain the confidentiality of your information in accordance with all national and local regulations.
You don’t have to respond to any question that you don´t want to answer and you may stop and exit the survey at any time and for any reason (boredom, fatigue, etc.).
This study has been approved by the Institutional Review Board of MUSC. If you feel you need any additional information, please e-mail Alejandra Schimmel at MUSC College of Nursing.
Filed under: Uncategorized | Tagged: advanced, care, life, needs, quality, supportive, survey |
THE "NEW" PROSTATE CANCER INFOLINK 
I would like to know if the biodegradable shield was being used in 2017. The shield protects the bowel during radiation treatment.
Thank you,
Richard Escobar
PS: Also l had full prostatectomy in 2015 and then had radiation in 2017. I don’t know if you want me to take the survey.
Dear Richard:
(a) When you use the term “biodegradable shield”, then if you are referring to the absorbable gel known as SpaceOAR hydrogel the answer is NO. This product wasn’t approved by the FDA until mid-2019, although the product was being tested in clinical trials in 2017. We should note that many healthcare insurance companies still do not consider this product to be “medically necessary” (see here as an example).
(b) You should only be responding to the survey if you have an advanced or AJCC Stage IV form of prostate cancer, which basically means either lymph node-positive (TxN1M0) or metastatic (TxNxM1) prostate cancer.